This act would establish a prohibition on health care insurers from requiring or conducting a review for prescription medicine that is used in the treatment of alcohol or opioid use disorder, that contains Methadone, Burenorphine, or Naltrexone or that was approved for the mitigation of opioid withdrawal symptoms.